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Abstract: INTRODUCTION: Lower urinary tract symptoms (LUTS) are highly prevalent, cause an
enormous economic burden on healthcare systems and significantly impair the quality of life (QoL) of
affected patients. The dependence of the LUT on complex central neuronal circuits makes it unique in
comparison to other visceral functions, such as the gastrointestinal tract, but also more vulnerable to
neurological diseases. METHODS AND ANALYSIS: This is a prospective neuroimaging study investi-
gating the supraspinal control of LUT function in healthy controls and in patients with non-neurogenic
LUTS. The clinical assessment will include medical history, neuro-urological examination, bladder diary,
urine analysis, urodynamic investigations, as well as standardised questionnaires regarding LUTS and
QoL. The acquisition of neuroimaging data will include structural assessments (T1-weighted imaging
and diffusion tensor imaging) as well as functional investigations using blood-oxygen-level dependent
sensitive functional MRI (fMRI) in a 3 T MR scanner. The fMRI will be performed during four dif-
ferent bladder tasks using an automated MR-compatible and MR-synchronised pump system. The first
three task-related fMRIs will consist of automated, repetitive filling of 100 mL warm (37°C) saline start-
ing with (1) an empty bladder, (2) a low prefilled bladder volume (100 mL) and (3) a high prefilled
bladder volume (persistent desire to void). The fourth task-related fMRI will comprise of automated,
repetitive filling of 100 mL cold (4-8°C) saline starting with an empty bladder. ETHICS AND DISSEM-
INATION: The local ethics committee approved this study (KEK-ZH-Nr. 2011-0346). The findings of
the study will be published in peer-reviewed journals and presented at national and international scien-
tific meetings. TRIAL REGISTRATION NUMBER: This study has been registered at clinicaltrials.gov
(http://www.clinicaltrials.gov/ct2/show/NCT01768910).
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Introduction: Lower urinary tract symptoms (LUTS)
are highly prevalent, cause an enormous economic
burden on healthcare systems and significantly impair
the quality of life (QoL) of affected patients. The
dependence of the LUT on complex central neuronal
circuits makes it unique in comparison to other
visceral functions, such as the gastrointestinal tract,
but also more vulnerable to neurological diseases.
Methods and analysis: This is a prospective
neuroimaging study investigating the supraspinal
control of LUT function in healthy controls and in
patients with non-neurogenic LUTS. The clinical
assessment will include medical history, neuro-
urological examination, bladder diary, urine analysis,
urodynamic investigations, as well as standardised
questionnaires regarding LUTS and QoL. The
acquisition of neuroimaging data will include structural
assessments (T1-weighted imaging and diffusion
tensor imaging) as well as functional investigations
using blood-oxygen-level dependent sensitive
functional MRI (fMRI) in a 3 T MR scanner. The fMRI
will be performed during four different bladder tasks
using an automated MR-compatible and
MR-synchronised pump system. The first three
task-related fMRIs will consist of automated, repetitive
filling of 100 mL warm (37°C) saline starting with
(1) an empty bladder, (2) a low prefilled bladder volume
(100 mL) and (3) a high prefilled bladder volume
(persistent desire to void). The fourth task-related fMRI
will comprise of automated, repetitive filling of 100 mL
cold (4–8°C) saline starting with an empty bladder.
Ethics and dissemination: The local ethics
committee approved this study (KEK-ZH-Nr. 2011–
0346). The findings of the study will be published in
peer-reviewed journals and presented at national and
international scientific meetings.
Trial registration number: This study has been
registered at clinicaltrials.gov (http://www.clinicaltrials.
gov/ct2/show/NCT01768910).
INTRODUCTION
Lower urinary tract symptoms (LUTS) are
highly prevalent, that is, about 11% in the
worldwide population in 2008, and fore-
casted to increase up to 20% until 2018.1 2
Moreover, LUTS cause an enormous eco-
nomic burden on each healthcare system,3 4
which is comparable to diabetes mellitus,5
and signiﬁcantly impair the quality of life
(QoL) of affected patients.6 7
For proper functioning, LUT structures,
that is, bladder, bladder neck, urethra and
urethral sphincter, rely on intact neuronal
innervations that are under the control of a
complex supraspinal network.8–10 The
dependence of the LUT on such complex
central neuronal circuits makes it unique in
comparison with other visceral functions, for
example, gastrointestinal tract, but also more
vulnerable to neurological diseases.10
Strengths and limitations of this study
▪ This will be the first study to identify brain net-
works of supraspinal LUT control in healthy sub-
jects and abnormalities within such brain
networks in patients with non-neurogenic LUTS
using structural and functional MRI techniques
in correlation with clinical measurements.
▪ Investigation of test–retest reliability has not yet
been performed for neuroimaging of LUT tasks.
However, this is important for the interpretation
of participants’ activations in regard to the valid-
ity of these activations, i.e. absolute and consist-
ent agreement (ICC) from visit to visit.
▪ Comparison of clinical correlates of treatment
efficacy in patients with non-neurogenic LUTS
with the associated changes in brain activity and
connectivity.
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Recent neuroimaging studies have shown that patients
with neurological disorders such as Parkinson’s
disease11–13 and spinal cord injury14 demonstrate differ-
ent supraspinal activity patterns compared with healthy
controls in response to LUT stimulation tasks, which
might represent a neural correlate to their LUTS.
Although there are several concepts regarding the
human LUT function and neuronal control in normal
and pathological conditions, the exact pathophysiological
mechanisms involved remain largely unknown.9 Despite the
popularity of resting-state functional MRI (RS-fMRI)15–20
and diffusion tensor imaging (DTI)21 in other ﬁelds in
neuroscience, these techniques have not been applied in
the context of supraspinal LUT control. There are only
two DTI studies published in regard to LUT control in
general: (1) a case report by Théaudin et al22 studying
spinal cord infarctions and clinical symptoms and (2) a
prospective study by van der Jagt et al23 investigating
architectural conﬁguration and microstructural proper-
ties of the sacral plexus.
As cortical and subcortical (eg, brainstem) brain
regions are crucial for voluntary LUT control,10 24 25
investigation of the supraspinal regions with high-
resolution imaging techniques, such as fMRI, can signiﬁ-
cantly contribute to increase our understanding of the
effects of supraspinal lesions and alterations related to
LUTS.10 26
In this study, we are aiming to identify supraspinal
areas associated with LUT control in healthy controls
and in patients with non-neurogenic LUTS. Task-related
blood-oxygen-level dependent (BOLD) and RS-fMRI
will be used along with structural MRI (T1-weighted
MRI and DTI). Hence, we will examine whether bladder
processing is already altered on the structural level and
on baseline (RS-fMRI) functional connectivity (FC). For
example, multiple repetition of the RS-fMRI will help to
understand whether manipulation of sensory perception
(induced by infusion and withdrawal) will alter the
default mode network20 of the brain. Furthermore, we
can examine volumetric parameters (eg, grey matter
concentration) by voxel-based morphometry (VBM),27
structural integrity and connectivity of white matter
tracts (DTI) as well as FC.
This unique and detailed multimodal imaging proto-
col should pinpoint to structural and functional process-
ing units involved during supraspinal LUT control and
should identify all dysfunctional neuronal components
in patients with disturbed LUT control.
Importantly, we will investigate the reliability28 of
BOLD signals in task-related fMRI and RS-fMRI in
healthy controls and patients with non-neurogenic
LUTS. The test–retest validation, that is, the intraclass
correlation coefﬁcient (ICC) for absolute or consistent
agreement of subject activations from visit to visit, has




This prospective research study will be conducted at the
University of Zürich, Zürich, Switzerland.
Study population and recruitment
According to the inclusion and exclusion criteria (table 1),
we will investigate patients with non-neurogenic LUTS and
healthy controls with an unimpaired LUT function.
Table 1 Inclusion and exclusion criteria for all participants
Groups Inclusion criteria Exclusion criteria
All participants ▸ Right handed
▸ Gender (female and male)
▸ Age limit: 18–55 years
▸ MR suitability
▸ Written informed consent
▸ Pregnancy or breast feeding
▸ Any craniocerebral injury or surgery
▸ Any permanent ferromagnetic implant
▸ Any previous surgery of LUT/genitalia
▸ Any anatomical anomaly of LUT/genitalia
▸ Any LUT malignancy
▸ PVR >150 mL
▸ UTI
Healthy controls ▸ Unimpaired LUT function
▸ No LUTS (3-day bladder diary)
– No episode of urinary
urgency/week
– Urinary frequency <8/24 h
▸ Impaired LUT function
▸ Any LUTS (3-day bladder diary)
– Any number of episodes of urinary urgency/week
– Urinary frequency >8/24 h
Patients with non-neurogenic
LUTS
▸ LUTS >6 months (3-day
bladder diary)
– ≥ 2episodes of urinary
urgency/week
– Urinary frequency >8/24 h
▸ Any neurological, psychological, metabolic or
cardiovascular disease
▸ Any concomitant treatment for the LUT
(eg, neuromodulation)
▸ SUI
▸ Indwelling catheters or necessity to perform ISC
ISC, intermittent self-catheterisation; LUTS, lower urinary tract symptoms; PVR, postvoid residual; SUI, stress urinary incontinence.
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Participants of both groups will be matched according to
age and gender.
Patients with non-neurogenic LUTS will be recruited
from our own department (Neuro-Urology, Balgrist
University Hospital, Zürich, Switzerland) and through
our partners at the University Hospital Zürich and the
Triemli Hospital Zürich. Eligible patients with non-
neurogenic LUTS and healthy controls will be invited to
a ﬁrst visit (screening) during which detailed informa-
tion about the study, in particular the aims, methods,
possible risks and side effects, will be given. After obtain-
ing written informed consent, the following data will be
collected: medical history, a 3-day bladder diary, urine
sample to exclude urinary tract infection (UTI) and
pregnancy in female participants, urodynamic para-
meters and postvoid residual measured by ultrasound as
well as standardised questionnaires regarding LUTS and
QoL. The validated German versions of these question-
naires will be used with permission of the International
Consultation on Incontinence Modular Questionnaire
((ICIQ), Bristol Urological Institute, Southmead
Hospital Bristol, UK) and will address the LUTS
(ICIQ-LUTS) in women (ICIQ-FLUTS) and men
(ICIQ-MLUTS), whereas the ICIQ-LUTSQoL will display
the QoL in regard to LUTS.
Determination of sample size
A power analysis was conducted using G*Power (http://
www.gpower.hhu.de). In order to have sufﬁcient power
(0.80) to detect a large effect size (0.80) between
healthy controls and patients with non-neurogenic
LUTS (signiﬁcance level 0.05), at least 21 participants
per group need to be recruited. To demonstrate post-
treatment effects in patients with non-neurogenic LUTS
compared with their baseline using the same power,
effect size and signiﬁcance level, at least 12 participants
for each treatment option are necessary. These sample
sizes are in line with earlier studies22 23 including our
own,14 29 which provided statistical evidence using small
collectives, that is, between 12 and 21 participants.
Study location
▸ Neuro-Urology, Spinal Cord Injury Centre and
Research, University of Zürich, Balgrist University
Hospital, Zürich, Switzerland.
▸ MR-Centre, University Hospital Zürich, Zürich,
Switzerland.
Partners
▸ Institute of Neuro-Radiology, University of Zürich,
University Hospital Zürich, Zürich, Switzerland.
▸ Departments of Urology and Gynaecology, University
Hospital Zürich, Zürich, Switzerland.
▸ Department of Urology and Gynaecology, Triemli
Hospital, Zürich, Switzerland.
Investigations
Following screening and study inclusion, all participants
will be scheduled for the second and third visits (ﬁrst
and second MRI measurements) at the MR-Centre.
Patients with non-neurogenic LUTS will return for a
fourth visit (third MRI measurement), either after
receiving treatment for LUTS or without treatment
acting as a direct control group within the patient
cohort (ﬁgure 1).
All MRI measurements (ﬁgure 2) will be performed
using a Philips Ingenia 3 T MR scanner (Philips Medical
Systems, Best, The Netherlands) with a 16-channel head
Figure 1 Timetable and characteristics of all four visits. LUTS, lower urinary tract symptoms; MRI, magnetic resonance imaging;
PVR, post void residual; QoL, quality of life.
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coil. During the second visit, we will acquire the follow-
ing neuroimaging data. Structural measurements will
contain T1-weighted MRI and DTI. Functional measure-
ments will comprise RS-fMRIs and task-related fMRIs.
Four different RS-fMRIs will be applied, that is, (1) at
baseline with an empty bladder, (2) with an empty
bladder plus transurethral catheter, (3) with a low pre-
ﬁlled bladder (100 mL saline, body warm) prior to
task-related fMRI and (4) after a task-related fMRI, to
understand whether manipulation of sensory perception
(induced by catheter or preﬁlling) will alter the default
mode network.20 The task-related fMRI will be acquired
during four different bladder tasks (ﬁgure 3). In order
to precisely ﬁll and drain the bladder (ie, speciﬁc
volume and duration of time), we designed an auto-
mated MR-compatible and MR-synchronised pump
system. In the ﬁrst three task-related fMRIs, we will
examine the effect of visceral bladder sensation by auto-
mated, repetitive ﬁlling with 100 mL body warm saline
starting with (1) an empty bladder, (2) a low preﬁlled
bladder and (3) a high preﬁlled bladder (persistent
desire to void). The fourth task-related fMRI will consist
of automated, repetitive ﬁlling of 100 mL cold (4–8°C)
saline starting with an empty bladder to investigate the
neural correlates of cold bladder sensation (ﬁgure 3).
Participants will rate their desire to void and their level
of pain using a displayed visual analogue scale and an
fMRI-compatible handheld response system.30
During the second MRI measurement (third visit,
1–4 weeks later), we will utilise a selection of MRI mea-
surements for the purpose of reliability analysis,28 that is,
RS-fMRI (baseline with an empty bladder plus trans-
urethral catheter) and task-related fMRI to compare
within and between groups.
The third MRI measurement will be identical to the
ﬁrst MRI measurement to evaluate post-treatment versus
pretreatment effects in patients with non-neurogenic
LUTS. The time from the start of treatment to the
fourth visit, that is, 5–7 weeks (ﬁgure 1), is necessary to
let clinical improvements develop.31 32
Safety
The staff involved in this study will be instructed and
trained according to the safety regulations of the
MR-Centre of the University Hospital Zürich. All partici-
pants will be asked to remove any ferromagnetic items,
for example, bra, earrings, chains, rings and piercings
prior to entering the scanner room. All participants will
be provided with standardised clinical scrubs instead of
wearing their own clothes. Before every MRI measure-
ment (visits 2, 3 and 4), urine samples will be analysed
from every participant in order to exclude UTI or preg-
nancy. In case of pregnancy, the participant will be
excluded from the study and referred to a gynaecologist.
In case of UTI, the participant will not undergo the
experiment, but will receive immediate antibiotic treat-
ment if the UTI is symptomatic or be treated depending
on further microbiological urine analysis in the absence
of UTI symptoms. The participant can be reassigned to
the study if the microbiological urine analysis shows no
evidence of a UTI or the UTI has been successfully
treated.
In the situation of an adverse event (AE) or a severe
AE (SAE), as deﬁned by the International Conference
on Harmonisation (ICH) Good Clinical Practice (GCP)
Guidelines (E6)33 and International Organization for
Standardization (ISO, 14155),34 appropriate actions will
be executed and the according body (principle
Figure 2 Schematic protocol of operational sequences of MRI measurements including functional MRI (fMRI): (A) first MRI
measurement, (B) second MRI measurement and (C) third MRI measurement.
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investigator, ethics committee) will be informed. All




A. BOLD signal intensity changes in a priori suprasp-
inal regions of interest (ROI), for example, pons,
insula, anterior cingulate cortex, thalamus, hypo-
thalamus, supplementary motor area and pre-
frontal cortex, during task-related fMRI in relation
to the speciﬁc condition, that is, infusion or to a
contrast, that is, low versus full bladder volume,
during two (healthy controls) or three (patients
with non-neurogenic LUTS) visits. The precise
selection of ROIs will be based on the coordinates
of the peak activations during task-related fMRI
taken from the Montreal Neurological Institute
(MNI) space.
B. Reliability of BOLD signal changes during RS-fMRI
and task-related fMRI across visits (eg, second and
third visits) in healthy controls and patients with
non-neurogenic LUTS.
C. BOLD signal changes in supraspinal ROIs during
task-related fMRI in patients with non-neurogenic
LUTS before and after treatment to quantify the link
between BOLD signal changes and treatment
efﬁcacy.
Figure 3 BOLD signal intensity changes during task-related fMRI in relation to the specific condition, that is, infusion or to a
contrast, that is, low versus full bladder volume, during two (healthy controls) or three (patients with non-neurogenic LUTS) visits.
Investigation of these changes will focus on supraspinal regions of interest (ROI) that are known from the existing literature, for
example, pons, insula, anterior cingulate cortex, thalamus, hypothalamus, supplementary motor area and prefrontal cortex. However,
the precise selection of ROIs will be based on the coordinates of the peak activations during task-related fMRI taken from the
Montreal Neurological Institute (MNI) space.
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Secondary
A. Structural differences between healthy controls and
patients with non-neurogenic LUTS, and changes in
the post-treatment versus pretreatment state of grey
matter concentration using VBM.
B. Structural connectivity (SC) and FC between suprasp-
inal ROIs to identify speciﬁc alterations with DTI35
between healthy controls and patients with non-
neurogenic LUTS (including post-treatment versus
pretreatment changes). This will include whole-brain
fractional anisotropy (FA) and mean diffusivity (MD)
comparison as well as probabilistic tractography
between ROIs (white matter ﬁbre structure).
C. Differences in BOLD signals during RS-fMRI
between healthy controls and patients with non-
neurogenic LUTS (including post-treatment versus
pretreatment changes) in regard to intrahemispheric
and interhemispheric connectivity.36 Investigation
will focus on whether these signals differ (1) already
at baseline or are inﬂuenced by the (2) presence of
a catheter, (3) by preﬁlling and/or (4) by task-
related fMRI.
D. Clinical scores (eg, bladder volume, urodynamic
parameters and level of desire to void during fMRI)
will be correlated to BOLD signal changes as well as
to structural markers (eg, grey matter volume or
number of white matter tracts between ROIs) using
regression analyses.
Data analysis
Clinical data, for example, urodynamic parameters,
3-day bladder diary outcome and questionnaire scores,
will be statistically analysed and compared between
groups using IBM’s Statistical Package for the Social
Sciences (SPSS) V.19.0 or newer (Armonk, New York,
USA) and will be presented with means and SDs or with
medians and IQRs as appropriate.
The neuroimaging data will be analysed using statistical
parametric mapping (SPM) V.8 or newer (Wellcome
Department of Imaging Neuroscience, University College
London, UK). Preprocessing of functional data from
each task-related fMRI will be carried out for each partici-
pant individually. The images will be realigned to the ﬁrst
scan, unwarped to control for movement-induced and
susceptibility-induced image distortions,37 spatially core-
gistered to the T1-weighted image and normalised to the
MNI anatomical standard space. At last, the functional
data will be smoothed spatially with an isotropic Gaussian
kernel. Thereafter, ﬁrst-level analysis using the general
linear model will be performed to create contrasts of
interest, for example, low versus full bladder or infusion
versus withdrawal.38 The six movement parameters will
be modelled as additional regressors to control for poten-
tial head motion.
Second-level factorial design will include at least (1)
one-sample t test to compute a mean for each group, (2)
two-sample t tests to compare healthy controls and
patients with non-neurogenic LUTS and (3) paired t tests
to evaluate post-treatment versus pretreatment effects in
patients with non-neurogenic LUTS. The ICC for
task-related and RS-fMRI reliability will be analysed using
the SPM-compatible ICC toolbox (http://www.kcl.ac.uk/
iop/depts/neuroimaging/research/imaginganalysis/
Software/ICC-Toolbox.aspx).
Association of individual (clinical) variables with
BOLD signal changes will be assessed by whole-brain
and ROI-based correlation analyses (correlation coefﬁ-
cients will be reported).
DTI data will be analysed using TBSS (http://fsl.
fmrib.ox.ac.uk/fsl/fsl4.0/tbss/index) and BrainVoyager
(http://www.brainvoyager.com/downloads/downloads.
html) with the following established DTI analyses:
whole-brain FA and MD comparison between groups
as well as probabilistic tractography between ROIs.
Seed and target regions, that is, ROIs will be deﬁned
(1) a priori using anatomic coordinates, for example,
from the SPM toolbox WFU_PickAtlas (http://fmri.
wfubmc.edu/software/PickAtlas) and (2) from peak
activations acquired from task-related fMRI and
RS-fMRI on the standard MNI space. Volumetric
changes in grey and white matter will be analysed
using VBM, for example, the VBM toolbox (http://
dbm.neuro.uni-jena.de/vbm) in SPM.
ETHICS AND DISSEMINATION
This cohort study will be performed in accordance with
the World Medical Association Declaration of Helsinki39
and the guidelines of the Swiss Academy of Medical
Sciences.40
Furthermore, handling of all personal data will strictly
comply with the federal law of data protection in
Switzerland.41
This study has been registered at clinicaltrials.gov
(http://www.clinicaltrials.gov/ct2/show/NCT01768910).
DISCUSSION
This study will investigate supraspinal LUT control in
healthy controls and patients with non-neurogenic
LUTS using a multimodal imaging protocol, that is,
structural (T1-weighted and DTI) and fMRI (RS-fMRI
and task-related fMRI), to examine haemodynamic
responses to LUT stimulation. From the acquired neuroi-
maging data, SC and FC, and structural integrity evalu-
ation of white matter tracts and grey matter
concentration (using VBM) will be analysed to identify
speciﬁc alterations of the supraspinal LUT control. In
addition, effects on the supraspinal LUT control after
treatment for LUTS (eg, antimuscarinergics or botu-
linum toxin) will be investigated. It is expected that this
study will provide new insights into the supraspinal neur-
onal mechanisms and networks responsible for LUT
control. The ﬁndings will help to verify, amend or adjust
neuronal circuitry models established from ﬁndings in
healthy controls, now in the context of patients with
non-neurogenic LUTS. The use of newer imaging and
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evaluation techniques has the potential to serve as quan-
tiﬁable outcome measures for therapy success and
provide evidence for non-responders of LUTS
treatment.
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